Early intravesical instillation of XXXX with oral administration of @entity1487 after transurethral resection for superficial @entity150 : preliminary results.

@entity1 @entity632 @entity1494 @entity150 @entity1487
In all, 199 @entity1 were entered in this study by 21 collaborating hospitals. @entity1 with superficial transitional cell @entity150 were randomized postoperatively into four groups. Group A received early (immediately and 2 days after transurethral resection) instillation of @entity632 (30 mg/30 mg); group B received early instillation of @entity632 with oral administration of @entity1487 (200 mg/day); group C received delayed (7 days after transurethral resection) instillation of @entity632 (30 mg/30 ml); and group D received delayed instillation of @entity632 with oral administration of @entity1487 (200 mg/day). All @entity1 subsequently received instillations weekly for 2 more weeks, and then every 2 weeks for a further 14 weeks. After 4 months, they received one instillation per month for 8 months. @entity1487 was administered p.o. for 1 year. The postoperative follow-up period was 12 months. After 3 and 6 months there were significant differences in the non-recurrence rates between groups B and C. After 12 months the overall non-recurrence rates were 87.9% in group A, 83.5% in group B, 89.2% in group C, and 82.8% in group D, and there were no significant differences among the four groups. The number of @entity1 entered and the follow-up period are not adequate for firm conclusions, and further studies are necessary. The main side effect was @entity1494 , which was observed in 38.8% of @entity1 in the early instillation groups and in 26.3% of those in the delayed instillation groups. No severe systemic side effects were observed in this study.
